| pubmed-article:12820322 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12820322 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:12820322 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:12820322 | lifeskim:mentions | umls-concept:C0004358 | lld:lifeskim |
| pubmed-article:12820322 | lifeskim:mentions | umls-concept:C0751688 | lld:lifeskim |
| pubmed-article:12820322 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
| pubmed-article:12820322 | lifeskim:mentions | umls-concept:C0041365 | lld:lifeskim |
| pubmed-article:12820322 | pubmed:issue | 2A | lld:pubmed |
| pubmed-article:12820322 | pubmed:dateCreated | 2003-6-24 | lld:pubmed |
| pubmed-article:12820322 | pubmed:abstractText | p53 autoantibodies (AAB) are a new serological parameter with unknown potential in patients with malignancies. The reason why and the mechanism by which they develop is still unclear. So far, only in a limited number of studies has the usefulness of p53 AAB in the follow-up of cancer patients been shown. In this study 32 patients with head and neck cancer, seropositive for p53 AAB in their serum detected with an ELISA, were followed-up for at least 42 months. In 9 out of 32 p53 seropositive AAB head and neck cancer patients a correlation with the clinical course of the disease was seen. The remaining 23 of the p53 AAB-positive patients did not demonstrate any significant AAB titer changes during the follow-up and no significant correlation with the clinical course was observed. In conclusion, the clinical value of p53 AAB as a tumor marker for patients with head and neck cancer seems to be limited. | lld:pubmed |
| pubmed-article:12820322 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12820322 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820322 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12820322 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820322 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820322 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12820322 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:BuhmannVolker... | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:MauneSteffenS | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:HoffmannMarku... | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:GottschlichSt... | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:MaassJan DJD | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:GörörghTiborT | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:Hoffmann-Faze... | lld:pubmed |
| pubmed-article:12820322 | pubmed:author | pubmed-author:RudertHeinric... | lld:pubmed |
| pubmed-article:12820322 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12820322 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:12820322 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12820322 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12820322 | pubmed:pagination | 913-5 | lld:pubmed |
| pubmed-article:12820322 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:meshHeading | pubmed-meshheading:12820322... | lld:pubmed |
| pubmed-article:12820322 | pubmed:articleTitle | p53 autoantibodies as tumor marker in head and neck squamous cell cancer. | lld:pubmed |
| pubmed-article:12820322 | pubmed:affiliation | Department of Otorhinolaryngology, Head and Neck Surgery, University Clinic Kiel, Arnold-Heller-Str. 14, 24105 Kiel, Germany. gottschlich@hno.uni-kiel.de | lld:pubmed |
| pubmed-article:12820322 | pubmed:publicationType | Journal Article | lld:pubmed |
